13
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Use of a mixed‐methods approach to develop a guidebook with messaging to encourage colorectal cancer screening among Black individuals 45 and older

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          Colorectal cancer (CRC) is the second leading cause of cancer‐related deaths in the United States and disproportionately impacts Black individuals. Here, we describe the mixed‐methods approach used to develop a tailored message guidebook to promote CRC screening among Black individuals in the setting of recently updated screening guidelines.

          Methods

          This mixed‐methods study included 10 in‐depth qualitative interviews and 490 surveys in a nationally representative sample of unscreened Black individuals age ≥ 45. Messages were developed based on American Cancer Society (ACS) and National Colorectal Cancer Roundtable (NCCRT) research findings, tested among Black individuals using MaxDiff analytic methods, and reviewed by a multi‐sector expert advisory committee of NCCRT members.

          Results

          The most frequently reported screening barrier in all age groups was self‐reported procrastination (40.0% in age 45–49, 42.8% for age 50–54, 34.2% for age ≥ 55). Reasons for procrastination varied by age and included financial concerns, COVID‐19 concerns, and fear of the test and bowel preparation. Additional screening barriers included lack of symptoms, provider recommendation, and family history of CRC. Most individuals age 45–49 preferred to receive screening information from a healthcare provider (57.5%); however, only 20% reported that a provider had initiated a screening conversation.

          Conclusions

          We identified age‐specific barriers to CRC screening and tailored messaging to motivate participation among unscreened Black people age ≥ 45. Findings informed the development of the NCCRT and ACS guidebook for organizations and institutions aiming to increase CRC screening participation in Black individuals.

          Abstract

          We performed a mixed‐methods study with 10 in‐depth qualitative interviews and 490 surveys in a nationally representative sample of unscreened Black individuals aged 45 and over to identify barriers to screening and effective messaging to prompt screening. The most frequently reported screening barrier in all age groups was self‐reported procrastination, and reasons for procrastination varied by age and included financial concerns, COVID‐19 concerns, and fear of the test and bowel preparation. Effective messages detailed the risk of colorectal cancer (CRC) in Black individuals and highlighted that CRC is preventable with screening.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: found
          • Article: not found
          Is Open Access

          Cancer statistics, 2022

          Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes. Incidence data (through 2018) were collected by the Surveillance, Epidemiology, and End Results program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2019) were collected by the National Center for Health Statistics. In 2022, 1,918,030 new cancer cases and 609,360 cancer deaths are projected to occur in the United States, including approximately 350 deaths per day from lung cancer, the leading cause of cancer death. Incidence during 2014 through 2018 continued a slow increase for female breast cancer (by 0.5% annually) and remained stable for prostate cancer, despite a 4% to 6% annual increase for advanced disease since 2011. Consequently, the proportion of prostate cancer diagnosed at a distant stage increased from 3.9% to 8.2% over the past decade. In contrast, lung cancer incidence continued to decline steeply for advanced disease while rates for localized-stage increased suddenly by 4.5% annually, contributing to gains both in the proportion of localized-stage diagnoses (from 17% in 2004 to 28% in 2018) and 3-year relative survival (from 21% to 31%). Mortality patterns reflect incidence trends, with declines accelerating for lung cancer, slowing for breast cancer, and stabilizing for prostate cancer. In summary, progress has stagnated for breast and prostate cancers but strengthened for lung cancer, coinciding with changes in medical practice related to cancer screening and/or treatment. More targeted cancer control interventions and investment in improved early detection and treatment would facilitate reductions in cancer mortality.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Colorectal cancer statistics, 2020

            Colorectal cancer (CRC) is the second most common cause of cancer death in the United States. Every 3 years, the American Cancer Society provides an update of CRC occurrence based on incidence data (available through 2016) from population-based cancer registries and mortality data (through 2017) from the National Center for Health Statistics. In 2020, approximately 147,950 individuals will be diagnosed with CRC and 53,200 will die from the disease, including 17,930 cases and 3,640 deaths in individuals aged younger than 50 years. The incidence rate during 2012 through 2016 ranged from 30 (per 100,000 persons) in Asian/Pacific Islanders to 45.7 in blacks and 89 in Alaska Natives. Rapid declines in incidence among screening-aged individuals during the 2000s continued during 2011 through 2016 in those aged 65 years and older (by 3.3% annually) but reversed in those aged 50 to 64 years, among whom rates increased by 1% annually. Among individuals aged younger than 50 years, the incidence rate increased by approximately 2% annually for tumors in the proximal and distal colon, as well as the rectum, driven by trends in non-Hispanic whites. CRC death rates during 2008 through 2017 declined by 3% annually in individuals aged 65 years and older and by 0.6% annually in individuals aged 50 to 64 years while increasing by 1.3% annually in those aged younger than 50 years. Mortality declines among individuals aged 50 years and older were steepest among blacks, who also had the only decreasing trend among those aged younger than 50 years, and excluded American Indians/Alaska Natives, among whom rates remained stable. Progress against CRC can be accelerated by increasing access to guideline-recommended screening and high-quality treatment, particularly among Alaska Natives, and elucidating causes for rising incidence in young and middle-aged adults.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society

              In the United States, colorectal cancer (CRC) is the fourth most common cancer diagnosed among adults and the second leading cause of death from cancer. For this guideline update, the American Cancer Society (ACS) used an existing systematic evidence review of the CRC screening literature and microsimulation modeling analyses, including a new evaluation of the age to begin screening by race and sex and additional modeling that incorporates changes in US CRC incidence. Screening with any one of multiple options is associated with a significant reduction in CRC incidence through the detection and removal of adenomatous polyps and other precancerous lesions and with a reduction in mortality through incidence reduction and early detection of CRC. Results from modeling analyses identified efficient and model-recommendable strategies that started screening at age 45 years. The ACS Guideline Development Group applied the Grades of Recommendations, Assessment, Development, and Evaluation (GRADE) criteria in developing and rating the recommendations. The ACS recommends that adults aged 45 years and older with an average risk of CRC undergo regular screening with either a high-sensitivity stool-based test or a structural (visual) examination, depending on patient preference and test availability. As a part of the screening process, all positive results on noncolonoscopy screening tests should be followed up with timely colonoscopy. The recommendation to begin screening at age 45 years is a qualified recommendation. The recommendation for regular screening in adults aged 50 years and older is a strong recommendation. The ACS recommends (qualified recommendations) that: 1) average-risk adults in good health with a life expectancy of more than 10 years continue CRC screening through the age of 75 years; 2) clinicians individualize CRC screening decisions for individuals aged 76 through 85 years based on patient preferences, life expectancy, health status, and prior screening history; and 3) clinicians discourage individuals older than 85 years from continuing CRC screening. The options for CRC screening are: fecal immunochemical test annually; high-sensitivity, guaiac-based fecal occult blood test annually; multitarget stool DNA test every 3 years; colonoscopy every 10 years; computed tomography colonography every 5 years; and flexible sigmoidoscopy every 5 years. CA Cancer J Clin 2018;68:250-281. © 2018 American Cancer Society.
                Bookmark

                Author and article information

                Contributors
                fmay@mednet.ucla.edu
                Journal
                Cancer Med
                Cancer Med
                10.1002/(ISSN)2045-7634
                CAM4
                Cancer Medicine
                John Wiley and Sons Inc. (Hoboken )
                2045-7634
                21 August 2023
                September 2023
                : 12
                : 18 ( doiID: 10.1002/cam4.v12.18 )
                : 19047-19056
                Affiliations
                [ 1 ] Division of Gastroenterology MGH Boston Massachusetts USA
                [ 2 ] KS&R New York New York USA
                [ 3 ] Ally Research Partners Atlanta Georgia USA
                [ 4 ] American Cancer Society National Colorectal Cancer Roundtable Kennesaw Georgia USA
                [ 5 ] Harvard TH Chan School of Public Health Boston Massachusetts USA
                [ 6 ] Vatche and Tamar Manoukian Division of Digestive Diseases, UCLA Kaiser Permanente Center for Health Equity and Jonsson Comprehensive Cancer Center, University of California Los Angeles Los Angeles California USA
                Author notes
                [*] [* ] Correspondence

                Folasade P. May, Vatche and Tamar Manoukian Division of Digestive Diseases, UCLA Kaiser Permanente Center for Health Equity and Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA 90095‐6900, USA.

                Email: fmay@ 123456mednet.ucla.edu

                Author information
                https://orcid.org/0000-0002-7919-4105
                https://orcid.org/0000-0002-0685-6446
                https://orcid.org/0000-0001-6706-8171
                Article
                CAM46461 CAM4-2023-04-1573.R1
                10.1002/cam4.6461
                10557828
                37602823
                5748d3a8-ec18-4840-a2b2-4e127e2aca89
                © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 07 July 2023
                : 04 April 2023
                : 06 August 2023
                Page count
                Figures: 4, Tables: 2, Pages: 10, Words: 5244
                Funding
                Funded by: Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles , doi 10.13039/100008623;
                Funded by: Jonsson Comprehensive Cancer Center , doi 10.13039/100007186;
                Funded by: National Cancer Institute , doi 10.13039/100000054;
                Award ID: P50CA244433
                Funded by: Pfizer , doi 10.13039/100004319;
                Funded by: Stand Up To Cancer , doi 10.13039/100009730;
                Funded by: Stem Cell Research Ablon Scholars Program
                Funded by: Trefler Foundation
                Categories
                Research Article
                RESEARCH ARTICLES
                Cancer Prevention
                Custom metadata
                2.0
                September 2023
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.3.4 mode:remove_FC converted:06.10.2023

                Oncology & Radiotherapy
                barriers,colon cancer,colonoscopy,colorectal cancer,screening,stool‐based testing

                Comments

                Comment on this article